Drug-metabolising CYP450 enzymes
Cytochrome P450 enzymes are the main xenobiotic inactivators in humans.
The main families of CYP450 enzymes involved in drug metabolism are the monooxygenases of the CYP1, CYP2 and CYP3 families.
Prescribers need to be aware of drug interactions with any of these enzymes that may alter responses to any other prescribed medications.
In a novel approach, recent research is suggesting that it may be possible to harness the CYP450-inactivating capacity of some clinically-approved drugs to manage CYP450 catalyzed metabolism of arachidonic acid (AA), to reduce pathological conditions associated with elevated levels of certain AA metabolites (namely epoxyeicosatrienoic acids [EETs] and hydroxyeicosatetraenoic acids [HETEs]). This strategy is discussed by El-Sherbeni and El-Kadi (2016): Repurposing Resveratrol and Fluconazole to Modulate Human Cytochrome P450-Mediated Arachidonic Acid Metabolism.
This webpage produced by Indiana University Department of Medicine lists clinically relevant CYP450 enzyme substrate drugs, and drugs which either inhibit or induce CYP450 activities, tabulated against the corresponding enzyme subtype.